Sonoma Pharmaceuticals, Inc. (SNOA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.26

From 52W high−70.91%

Volume147395.00

Market cap$6.13M

P/E (TTM)—

P/S (TTM)0.3x

Div yield—

Key dataSep 18, 2026

Open

$1.26

From 52W high

−70.91%

Volume

147395.00

Market cap

$6.13M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

45.4

MomentumView details →

1D Return

+1.59%

YTD Return

−65.38%

SummaryUpdated Jun 1, 2026

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is a specialty pharmaceutical company founded in 1999 and originally incorporated as Oculus Innovative Sciences before rebranding in December 2016. Based in Woodstock, Georgia, the company has developed a unique focus on stabilized hypochlorous acid (HOCl) technology for medical and healthcare applications. Since going public in 2007, Sonoma has built a portfolio of HOCl-based products spanning wound care, dermatology, eye care, oral care, and animal health markets across the United States, Latin America, Europe, and other international markets.

Ask drillr about Sonoma Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

0.1x

P/S (TTM)

0.3x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

38.91%

Net Margin

−10.33%

EBITDA Margin

−7.27%

ROE (TTM)

−34.33%

ROA (TTM)

−12.50%

Asset Turnover

1.37x

GrowthView details →

Revenue YoY

+47.00%

EPS YoY

+53.26%

FCF YoY

—

Revenue CAGR 3Y

+13.74%

EPS CAGR 3Y

+32.26%

EBITDA YoY

+52.94%

MomentumView details →

1D Return

+1.59%

YTD Return

−65.38%

1Y Return

−69.86%

RSI (14)

45.4

vs 50D SMA

−0.17%

vs 200D SMA

−38.81%

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

2.99x

Quick Ratio

2.29x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.02

EPS Surprise

106.67%

Beats (12Q)

7/12

Next Q EPS Est

−$0.10

Avg Surprise (4Q)

69.02%

Rev Surprise

28.38%

Financials snapshotView financials →

Revenue (TTM)

21.92M

Net Income (TTM)

−2.26M

Op. CF (TTM)

−2.03M

Next earningsNov 16, 2026 →

Latest newsMore news →

Sonoma Pharmaceuticals Inc. reported its first-quarter financial results, achieving record quarterly revenue and turning EBITDA positive for the first time, with a net loss of 9 cents per share compared to a loss of 76 cents per share a year earlier.45d ago

Similar companies

Gelteq Limited Ordinary SharesGELS Shuttle Pharmaceuticals Holdings, Inc.SHPH PRF Technologies Ltd.PRFX Sunshine Biopharma, Inc.SBFM RedHill Biopharma Ltd.RDHL China SXT Pharmaceuticals, Inc.SXTC Find similar companies →

Latest newsMore news →